secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2026-06-22T21:00:16+00:00
Accession:  0001193125-26-277653
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon stockholders approve increase in authorized common shares from 300M to 450M
--------------------------------------------------------------------------------

- Elected three Class III directors: David-Alexandre C. Gros, M.D., Jan Hillson, M.D., James Robinson for terms ending 2029.
- Authorized share increase approved with 52.3M for, 3.7M against, 294k abstain.
- Ratified Deloitte & Touche as independent auditor for FY 2026.
- Certificate of Amendment effective June 22, 2026, filed with Delaware Secretary of State.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526277653/0001193125-26-277653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526277653/eldn-20260618.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-277653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer